Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CardioNet, Inc. (BEAT)
|
Add to portfolio |
|
|
|
| Price: |
$3.64
| | Metrics |
| OS: |
25.4
|
M
| |
-16
|
% ROE
|
| Market cap: |
$92.4
|
M
| |
-35
|
% ROIC
|
|
Net cash:
|
$18.3
|
M
| |
$0.72
|
per share
|
|
EV:
|
$74.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$37.0
|
k
| |
2001.7
|
x EV/EBITDA
|
|
EBIT
|
($10.3)
|
M
| |
|
|
| EPS |
($0.43)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 12/22/2020 |
GN
| SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – BEAT, HBAN, PS, CKH |
| 12/18/2020 |
GN
| (BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price? |
| 07/30/2020 |
GN
| BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results |
| 07/29/2020 |
GN
| BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary |
| 07/23/2020 |
GN
| BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020 |
| 04/29/2020 |
GN
| BioTelemetry, Inc. to Release First Quarter 2020 Earnings Results on May 6, 2020 |
| 04/27/2020 |
GN
| BioTelemetry, Inc. to Move to Virtual-only Annual Stockholder Meeting for 2020 |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 111.5 | 119.0 | 119.9 | 140.6 | 120.5 | 73.0 | 33.9 | 30.9 |
| Revenue growth | -6.3% | -0.8% | -14.7% | 16.7% | 65.0% | 115.2% | 9.6% | |
| Cost of goods sold | 45.6 | 49.1 | 47.5 | 48.7 | 39.9 | 25.5 | 12.7 | 17.0 |
| Gross profit | 65.9 | 69.9 | 72.4 | 91.9 | 80.5 | 47.5 | 21.2 | 14.0 |
| Gross margin | 59.1% | 58.8% | 60.4% | 65.4% | 66.9% | 65.0% | 62.6% | 45.2% |
| Sales and marketing | 25.6 | 27.8 | 29.3 | 34.7 | 21.1 | 16.0 | 6.4 | 6.5 |
| Research and development | 4.7 | 5.7 | 4.9 | 5.8 | 4.0 | 3.8 | 3.6 | 3.4 |
| General and administrative | 32.6 | 35.0 | 34.7 | 39.2 | 27.6 | 19.4 | 15.6 | 13.9 |
| EBITA | -10.0 | -11.3 | -19.3 | -19.8 | 10.7 | 1.0 | -4.5 | -9.7 |
| EBITA margin | -9.0% | -9.5% | -16.1% | -14.1% | 8.9% | 1.4% | -13.2% | -31.3% |
| Amortization of intangibles | 1.3 | 1.2 | 0.4 | 0.9 | 1.0 | 0.8 | | |
| EBIT | -11.4 | -12.5 | -19.7 | -20.6 | 9.7 | 0.2 | -4.5 | -9.7 |
| EBIT margin | -10.2% | -10.5% | -16.4% | -14.7% | 8.0% | 0.3% | -13.2% | -31.3% |
| Pre-tax income | -13.1 | -61.2 | -19.6 | -20.5 | 10.7 | -0.4 | -7.6 | -11.5 |
| Income taxes | -0.9 | 0.2 | 0.3 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 |
| Tax rate | 6.9% | | | | 13.9% | 0.0% | 0.0% | 0.0% |
| Net income | -12.2 | -61.4 | -19.9 | -20.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -10.9% | -51.6% | -16.6% | -14.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| |
| Diluted EPS | ($0.49) | ($2.51) | ($0.82) | ($0.86) | $0.29 | ($2.89) | ($2.63) | ($4.04) |
| Shares outstanding (diluted) | 24.9 | 24.4 | 24.1 | 23.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|